GLOBAL HASHIMOTO’S THYROIDITIS DRUG MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)

Global Hashimoto’s Thyroiditis Drug Market, By Drug Type (Wearable Devices and Non-wearable Devices), By Features (Basic Sleep Tracking, Sleep Staging, Heart Rate Monitoring, Respiratory Monitoring, and Others), By End User (Hospitals, Sleep Centers, Home Care Settings, and Diagnostic Laboratories), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa).

Recent Developments

Key Developments

In 2023, IBSA Pharma Inc., a multinational pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) approved two changes to the label of levothyroxine sodium, an oral solution that is aimed to treat hypothyroidism. The first change included the use of levothyroxine sodium combined with proton pump inhibitor (PPI) therapy. The second change included timing to administer levothyroxine sodium.
On January 26, 2024, AbbVie Inc. announced the strengthening of its manufacturing capabilities by expansion of its Singapore manufacturing facility. This new investment will add more than 100 jobs and new biologics manufacturing capacity to AbbVie's global network. AbbVie's Singapore plant is a state-of-the-art small-molecule and biologics manufacturing facility which is serving markets worldwide. This new investment will add 24,000 liters of biologics drug-substance capacity to AbbVie's global manufacturing network and thus support current products as well as emerging immunology and oncology compounds within AbbVie's pipeline.

Global Hashimoto’s Thyroiditis Drug Market Report Snapshots